Mesoblast Limited Announce Long-Lasting And Sustained Effect By Allogeneic Cells In Knee Osteoarthritis Preclinical Trials

Australia’s adult stem cell company, Mesoblast Limited (ASX: MSB; USOTC: MBLTY), announced successful long-term results in its osteoarthritis preclinical trials. A single injection of its proprietary allogeneic, or “off-the-shelf”, adult stem cells into arthritic knees provided sustained protection against cartilage destruction and degeneration for up to nine months.

More: continued here

Filed under: Arthritis on April 22nd, 2008